KRAS and neoplasm: revealed significantly elevated PD-L1 expression levels in both tumor tissues and cell lines derived from KRAS-mutant lung adenocarcinoma patients, compared to their KRAS-wild-type, EGFR-mutated, and ALK-mutated counterparts (105).